Jan 06, 2022 / 06:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone. Thank you for joining us at the Goldman Sachs CEO and Scripted Conference 2022. We're pleased to have Bob Bradway, Chairman and CEO of Amgen. Bob, thank you for joining us, and let me turn it over to you for opening remarks.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Okay. Thank you, Salveen. Thanks for having us, and happy New Year to you and all of your guests at the conference. Let me just say a few remarks, Salveen, and then we can jump straight into Q&A. Obviously, we're excited about how things are setting up for us.
We think we're in a position to deliver attractive results for the long term and that we expect will be built off the strong base that we've established now for Repatha, Otezla, our bone health franchise, which, of course, comprises Prolia and EVENITY. So we're excited about how we think those will contribute to long-term growth. And in addition, our biosimilars franchise, we think is really delivering now as
Amgen Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript
Jan 07, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers